Alx Oncology Holdings Stock In The News

ALXO Stock  USD 0.49  0.04  6.83%   
Our overall analysis of Alx Oncology's news coverage and content from conventional and social sources shows investors' bearish mood towards Alx Oncology Holdings. The specific impact of Alx Oncology news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Alx Oncology's overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Alx Oncology headlines in addition to utilizing other, more conventional financial analysis modules. Check out Alx Oncology Backtesting and Alx Oncology Hype Analysis.

Alx Oncology Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
https://www.globenewswire.com/news-release/2025/05/30/3091026/0/en/ALX-Oncology-to-Present-at-the-Jefferies-2025-Global-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
https://www.globenewswire.com/news-release/2025/05/13/3080030/0/en/ALX-Oncology-to-Host-R-D-Webcast-Event-Highlighting-its-Novel-EGFR-Targeting-Antibody-Drug-Conjugate-ALX2004-on-May-20-2025.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
https://www.globenewswire.com/news-release/2025/05/08/3077254/0/en/ALX-Oncology-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
https://www.globenewswire.com/news-release/2025/05/02/3073234/0/en/ALX-Oncology-to-Report-First-Quarter-2025-Financial-Results-on-May-8-2025.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology Announces Encouraging Final...
https://www.globenewswire.com/news-release/2025/04/25/3068527/0/en/ALX-Oncology-Announces-Encouraging-Final-Results-from-Phase-1-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-B-cell-Non-Hodgkin-Lymphom.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology Reports ASPEN-03 and ASPEN-...
https://www.globenewswire.com/news-release/2025/04/25/3068327/0/en/ALX-Oncology-Reports-ASPEN-03-and-ASPEN-04-Phase-2-Trials-Evaluating-Evorpacept-with-a-Checkpoint-Inhibitor-for-the-Treatment-of-Head-and-Neck-Cancers-Did-Not-Meet-Primary-Endpoint.html
 Neutral
Yahoo News
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
https://finance.yahoo.com/news/why-alx-oncology-holdings-inc-182714950.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
https://www.globenewswire.com/news-release/2025/03/06/3038596/0/en/ALX-Oncology-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Update.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology Presents Positive Updated D...
https://www.globenewswire.com/news-release/2025/01/23/3014205/0/en/ALX-Oncology-Presents-Positive-Updated-Data-from-ASPEN-06-Phase-2-Trial-Demonstrating-Evorpacept-Generates-Strong-Response-and-Durable-Clinical-Benefit-in-Patients-with-HER2-Positi.html
 Neutral
Macroaxis News: globenewswire.com
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
https://www.globenewswire.com/news-release/2025/01/22/3013859/0/en/ALX-Oncology-Reports-Inducement-Grant-as-permitted-by-the-Nasdaq-Listing-Rules.html
 Bullish

Alx Oncology Holdings Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Alx and other traded companies coverage with news coverage. We help investors stay connected with Alx headlines for the 18th of June 2025 to make an informed investment decision based on correlating the impacts of news items on Alx Stock performance. Please note that trading solely based on the Alx Oncology Holdings hype is not for everyone as timely availability and quick action are needed to avoid losses.
Alx Oncology's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Alx Oncology Holdings investors visualize upcoming and past events in order to time the market based on Alx Oncology Holdings noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alx Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alx Oncology's short interest history, or implied volatility extrapolated from Alx Oncology options trading.
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out Alx Oncology Backtesting and Alx Oncology Hype Analysis.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.45)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.51)
Return On Equity
(1.03)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.